Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06652464
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-15
Brief Title:
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Relationship Between Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Specialized pro-resolving mediators SPMs which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids have been shown to suppress inflammation and promote timely resolution of inflammation They are mainly divided into four categories lipoxins resolvins protectins and maresins The study will compare Maresin-1 and Resolvin-D1 levels in ulcerative colitis patients with those in the control group
Detailed Description:
Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation of the superficial colonic mucosa which starts in the rectum and diffusely extends throughout the colon with alternating periods of flare-ups and remission The diagnosis activity and treatment outcomes of ulcerative colitis are evaluated through a combination of symptoms clinical examination laboratory tests radiology endoscopy and histological findings Assessing inflammatory activity is crucial for approaching the disease and shaping treatment Therefore studies have aimed to identify the ideal disease marker In recent years there has been a search for non-invasive easy and quick laboratory markers to evaluate disease activity and treatment response The optimal marker should be disease-specific accurately reflect disease activity be easily applicable in clinical practice and identify patients at risk of relapse Many clinical activity indicators and non-invasive markers have been used for this purpose but they have only provided indirect findings in assessing disease activity
When the impact of inflammation reaches a certain stage a number of endogenous pro-resolving lipid mediators are synthesized to promote the resolution of inflammation These mediators remove pro-inflammatory mediators and inflammatory cells from the site repair damaged tissues and eventually terminate inflammatory responses If they cannot be produced at adequate levels andor fail to function properly inflammation cannot resolve during this process leading to a chronic inflammatory phase Several endogenous pro-resolving lipid mediators such as maresins lipoxins protectins and resolvins have been discovered in recent years through scientific research Many studies in the literature indicate that these mediators maintain a balance of pro-inflammatory chemical mediators reduce the tissue infiltration of PMNLs polymorphonuclear leukocytes enhance macrophage efferocytosis and phagocytosis and decrease collateral tissue damage caused by phagocytic cells
Maresin-1 and resolvin-D1 are lipid molecules synthesized in macrophages and are produced from omega-3 polyunsaturated fatty acid docosahexaenoic acid DHA and have been identified as a novel type of inflammatory mediator Multiple studies have shown that Maresin-1 can control the inflammatory response by inhibiting neutrophil infiltration downregulating the production of pro-inflammatory mediators inhibiting NF-κB activation restoring the TregTh17 balance and alleviating endoplasmic reticulum stress
Resolvin-D1 and Maresin-1 exhibit anti-inflammatory activityThe study aims to compare the serum levels of Resolvin-D1 RvD1 and Maresin-1 Mar1 during remission and active phases of ulcerative colitis with those in a control group to evaluate whether they correlate with clinical and laboratory features and to determine their potential use as markers reflecting inflammation in the diagnosis of ulcerative colitis
When the impact of inflammation reaches a certain stage a number of endogenous pro-resolving lipid mediators are synthesized to promote the resolution of inflammation These mediators remove pro-inflammatory mediators and inflammatory cells from the site repair damaged tissues and eventually terminate inflammatory responses If they cannot be produced at adequate levels andor fail to function properly inflammation cannot resolve during this process leading to a chronic inflammatory phase Several endogenous pro-resolving lipid mediators such as maresins lipoxins protectins and resolvins have been discovered in recent years through scientific research Many studies in the literature indicate that these mediators maintain a balance of pro-inflammatory chemical mediators reduce the tissue infiltration of PMNLs polymorphonuclear leukocytes enhance macrophage efferocytosis and phagocytosis and decrease collateral tissue damage caused by phagocytic cells
Maresin-1 and resolvin-D1 are lipid molecules synthesized in macrophages and are produced from omega-3 polyunsaturated fatty acid docosahexaenoic acid DHA and have been identified as a novel type of inflammatory mediator Multiple studies have shown that Maresin-1 can control the inflammatory response by inhibiting neutrophil infiltration downregulating the production of pro-inflammatory mediators inhibiting NF-κB activation restoring the TregTh17 balance and alleviating endoplasmic reticulum stress
Resolvin-D1 and Maresin-1 exhibit anti-inflammatory activityThe study aims to compare the serum levels of Resolvin-D1 RvD1 and Maresin-1 Mar1 during remission and active phases of ulcerative colitis with those in a control group to evaluate whether they correlate with clinical and laboratory features and to determine their potential use as markers reflecting inflammation in the diagnosis of ulcerative colitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None